Literature DB >> 2669283

Local events in graft rejection.

P Häyry1, R Renkonen, D Leszczynski, P Mattila, S Tiisala, J Halttunen, J P Turunen, T Partanen, K Rinta.   

Abstract

It appears that allograft rejections can be considered as a series of cellular and molecular cascades of inflammation triggered by the immune response. In acute rejection, inflammatory changes with a prominent blast cell component dominate. The main result is toxic damage of several parenchymal components, particularly the microvascular endothelium, resulting in necrosis of the parenchyma and loss of the allograft within days after transplantation. In the chronic type of rejection, inflammation also exists, but the major manifestations are different. Adventitial inflammation and perivascular cuffing of leukocytes result in concentric intimal proliferation and atherosclerosis. Very little experimental data exist, at present, on the mechanisms of transplant atherosclerosis and chronic rejection.

Entities:  

Mesh:

Year:  1989        PMID: 2669283

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis.

Authors:  R H Hruban; W E Beschorner; W A Baumgartner; S M Augustine; H Ren; B A Reitz; G M Hutchins
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

2.  Screening of a HUVEC cDNA library with transplant-associated coronary artery disease sera identifies RPL7 as a candidate autoantigen associated with this disease.

Authors:  A T Linke; B Marchant; P Marsh; G Frampton; J Murphy; M L Rose
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

3.  Changes in T lymphocyte subsets and intracellular cytokines after transfer of chemically extracted acellular nerve allografts.

Authors:  Wei Li; Wen-Wen Wu; Xing-Shi Lin; Shu-Xun Hou; Hong-Bin Zhong; Di-Ke Ruan
Journal:  Mol Med Rep       Date:  2012-01-09       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.